By Cecilia Butini 
 

Novartis AG said Monday that a Phase 3 trial to evaluate a drug for use in lung cancer patients didn't meet its primary endpoints.

The Swiss pharma major said the trial, named CANOPY-1, didn't demonstrate statistical significance in overall survival and progression-free survival, meaning the time that a patient can live without the disease progressing.

The trial evaluated canakinumab, a monoclonal antibody, in combination with chemotherapy for patients with non-small cell lung cancer.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

October 25, 2021 01:43 ET (05:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Novartis Charts.